Enrolling Studies

Studies in Progress

SFP is a novel, investigational, continuous iron therapy in late-stage clinical development, designed to treat iron deficiency anemia in ESRD patients. In contrast to intravenous (IV) iron delivery, SFP is a proprietary, water-soluble iron that travels to the bloodstream and binds directly to apo-transferrin and then travels to bone marrow to assist in forming a healthy red blood cell, similar to normal physiologic dietary iron intake. SFP is a continuous iron replacement treatment, delivering small doses of iron during every dialysis session, to replenish the 5-7mg of iron lost during the dialysis procedure, thereby maintaining hemoglobin in the target range as per Kidney Disease Quality Outcomes Initiative (KDQOI) recommendations.

Hyponatremia is the most common electrolyte disorder affecting hospitalized patients. While studies have demonstrated its significant impact, more evidence and greater understanding are needed to assess the true burden and costs of hyponatremia in the hospital setting. Your participation in the registry will help provide valuable information that can help improve the quality of hyponatremia management.Objectives: Evaluate the burden of dilutional hyponatremia, compare the effectiveness of current treatments,and determine resource utilization in relation to the treatment of hyponatremia

A sprained ankle, also known as an ankle sprain, twisted ankle, rolled ankle, ankle injury or ankle ligament injury, is a common medical condition where one or more of the ligaments of the ankle is torn or partially torn.The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains under 'in-use' conditions, in particular with regard to pain relief.

A study for an investigational new drug intended to control phosphorus levels in the blood of patients with chronic kidney disease (CKD) who are being treated with hemodialysis (a process to rid your body of harmful waste material and excessive fluids). This study is for patients already taking a phosphate binder medicine. The investigational drug has already been proven to be safe and effective for treatment during previous studies. This study is comparing the new medication with one that is already on the market.

Secondary hyperparathyroidism (SHPT) is common in people who have chronic kidney disease (CKD). Individuals with SHPT often have high parathyroid hormone levels (PTH) in their blood and may develop large parathyroid glands in the neck. The purpose of this study is to determine whether the use of Sensipar (Cinacalcet) alone is able to control the level of PTH in the blood as well or better than twith Vitamin D treatment combined in hemodialysis patients with SHPT.